The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects. 1995

L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
Department of Psychopharmacology, Faculty of Pharmacy, Rudolf Magnus Institute for Neurosciences, Utrecht University, Netherlands.

The effects of flesinoxan, a selective 5-HT1A receptor agonist, were studied under basal non-stress conditions and in the shock-probe burying paradigm. Flesinoxan (1 and 3 mg/kg s.c.) significantly reduced burying and freezing behaviour, indicating clear anxiolytic properties. Under non-stress conditions, injection of 3 mg/kg flesinoxan significantly enhanced plasma corticosterone and glucose levels, whereas prolactin secretion was significantly enhanced after both 1 mg/kg and 3 mg/kg flesinoxan. Flesinoxan (1 and 3 mg/kg) did not suppress shock-probe stress-induced rises in plasma corticosterone and glucose levels. The enhanced plasma prolactin levels induced by flesinoxan were not further affected by shock-probe exposure. Our data show that the anxiolytic effects of flesinoxan in the shock-probe burying paradigm are not related to increases in plasma corticosterone and glucose levels.

UI MeSH Term Description Entries
D008297 Male Males
D009490 Neurosecretory Systems A system of NEURONS that has the specialized function to produce and secrete HORMONES, and that constitutes, in whole or in part, an ENDOCRINE SYSTEM or organ. Neuroendocrine System,Neuroendocrine Systems,Neurosecretory System,System, Neuroendocrine,System, Neurosecretory,Systems, Neuroendocrine,Systems, Neurosecretory
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003345 Corticosterone An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004597 Electroshock Induction of a stress reaction in experimental subjects by means of an electrical shock; applies to either convulsive or non-convulsive states. Electroconvulsive Shock,Electroconvulsive Shocks,Electroshocks,Shock, Electroconvulsive,Shocks, Electroconvulsive
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors

Related Publications

L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
September 1996, Psychopharmacology,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
January 1998, European journal of pharmacology,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
April 1994, European journal of pharmacology,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
April 1994, The Journal of pharmacology and experimental therapeutics,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
May 1994, British journal of pharmacology,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
October 2002, Psychopharmacology,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
May 1997, European journal of pharmacology,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
June 2002, European journal of pharmacology,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
November 1989, Journal of cardiovascular pharmacology,
L Groenink, and J Van der Gugten, and P M Verdouw, and R A Maes, and B Olivier
August 1994, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!